LVP software of the Ivenix Infusion System (IIS); LVP-SW-0004
Publicado el 20 de marzo de 2024 · Inicio del retiro: 10 de mayo de 2023
Resumen
FDA registra el retiro Z-1283-2024 de dispositivos médicos de Clase II, publicado el 20 de marzo de 2024 e iniciado el 10 de mayo de 2023. Empresa responsable: Fresenius Kabi USA, LLC; Estado: Completado; Cantidad reportada: 6 US; Lote: UDI-DI 00811505030122 Software versions 5.2.1/5.2.2. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Completed — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Retroactively reported corrections from 2023: 1) A software defect may cause an incorrect (Fail-Stop) alarm when an administration set is loaded or coupled while the pump is executing the power-up sequence. May lead to delay in therapy. 2) Alert is not annunciated informing the clinician that the bolus cannot be delivered when the entered bolus dose exceeds the Care Profile Hard Rate Max limit and Rapid Bolus is selected. May lead to over infusion. Both issues were resolved in all fielded product in software version 5.8.0, which was installed in affected units May thru August 2023.
Qué hacer
Voluntary: Firm initiated · Other
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Fresenius Kabi USA, LLC
- Distribuidor
- US Nationwide distribution to the states of CA, CO, NJ, WI, UT.
- Lote
- UDI-DI 00811505030122 Software versions 5.2.1/5.2.2
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDATyenne (tocilizumab-aazg) Injection, 400 mg/20 mL (20 mg/mL), 20 mL vial, Rx Only, Manufactured by Fresenius2 de septiembre de 2026
- FDAMorphine Sulfate Injection, USP, 2 mg /mL, 1 mL single-dose Simplist prefilled syringes, For Intramuscular or26 de agosto de 2026
- FDAXylocaine (lidocaine HCl Injection, USP), 1%, 200 mg per 20 mL (10 mg per mL), 25 Multiple-Dose Vials, 20 mL,29 de julio de 2026
- FDAGlycopyrrolate Injection, USP, 1 mg per 5 mL (0.2 mg per mL), 25 x 5 mL fill in a 6.5 mL vial, Rx only,29 de julio de 2026
- FDALVP software of the Ivenix Infusion System (IIS), LVP-SW-000420 de marzo de 2024
- FDACERENOVUS CEREBASE DA Guide Sheath, Part Numbers: a) GS9080SD; b) GS9090SD; c) GS9095SD; Vascular20 de marzo de 2024
Preguntas sobre este retiro
¿LVP software of the Ivenix Infusion System (IIS); LVP-SW-0004 fue retirado del mercado?
Sí. FDA publicó el retiro Z-1283-2024 el 20 de marzo de 2024. Peligro reportado: Retroactively reported corrections from 2023: 1) A software defect may cause an incorrect (Fail-Stop) alarm when an administration set is loaded or coupled while the pump is executing the power-up sequence. May lead to delay in therapy. 2) Alert is not annunciated informing the clinician that the bolus cannot be delivered when the entered bolus dose exceeds the Care Profile Hard Rate Max limit and Rapid Bolus is selected. May lead to over infusion. Both issues were resolved in all fielded product in software version 5.8.0, which was installed in affected units May thru August 2023.
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Other